What is the brand name for the oral combination of tegafur and uracil tablets?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Brand Name for Tegafur and Uracil Tablets

The brand name for the oral combination of tegafur and uracil tablets is UFT (also marketed as UFUR or ORZEL in some regions).

Background and Nomenclature

UFT is the internationally recognized brand name for the fixed-dose combination of tegafur and uracil in a 4:1 molar ratio 1, 2. This oral fluoropyrimidine chemotherapy agent has been commercially available since 1983, initially in Japan, and has since been studied extensively in various malignancies 1.

Alternative Brand Names by Region:

  • UFUR: Used in some Asian markets, particularly in head and neck cancer maintenance therapy 3
  • ORZEL: The brand name used when UFT is combined with calcium folinate (leucovorin) in the United States 1

Mechanism and Clinical Context

The combination works through a unique mechanism where:

  • Tegafur serves as a prodrug that is converted to 5-fluorouracil (5-FU)
  • Uracil competitively inhibits dihydropyrimidine dehydrogenase (DPD), the enzyme that degrades 5-FU
  • This results in sustained 5-FU concentrations in both plasma and tumor tissue, mimicking continuous infusion 5-FU but via oral administration 1, 2

Clinical Applications

UFT has demonstrated efficacy across multiple tumor types:

  • Colorectal cancer: When combined with calcium folinate, showing similar efficacy to IV 5-FU regimens with better tolerability 1
  • Lung adenocarcinoma: Particularly as adjuvant therapy for stage I disease, where it improved overall survival 4
  • Gastric carcinoma: Standard adjuvant therapy in Japan with approximately 20% response rate in advanced disease 2
  • Head and neck cancer: Emerging role as maintenance therapy in both resectable and unresectable disease 3, 5

The oral formulation offers significant advantages in patient convenience and potentially reduced toxicity compared to intravenous 5-FU regimens, though it is not widely available in all markets 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.